- 24Jul, 2025
As we navigate the complexities of modern medicine, a quiet threat remains: multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae. Super gonorrhea is a prime example of how bacteria can outsmart our best defenses. At TAXIS, we are diving headfirst into the science of combating antimicrobial AMR.
Antibiotic resistance – or antimicrobial resistance (AMR) – has been making headlines for decades. At TAXIS Pharmaceuticals, we have been working since 2009 on the development of compounds that combat antimicrobial resistance.
TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia. Originally published in NORTH BRUNSWICK, N.J., May 1, 2024 /PRNewswire-PRWeb/
FtsZ inhibitors represent a new drug class as no drugs using this mode of action (MOA) have been approved by regulators. In this paper, we present the screening and evaluation of a benzamide class that is functionalized at the alkoxy fragment targeting Gram-negative bacteria.
- 24Oct, 2024
Efflux pumps in Gram-negative bacteria such as Pseudomonas aeruginosa provide intrinsic antimicrobial resistance by facilitating the extrusion of a wide range of antimicrobials. Approaches for combating efflux-mediated multidrug resistance involve, in part, developing indirect antimicrobial agents capable of inhibiting efflux, thus rescuing the activity of antimicrobials previously rendered inactive by efflux. Herein, TXA09155 is presented as a novel efflux pump inhibitor (EPI) formed by conformationally constraining our previously reported EPI TXA01182. TXA09155 demonstrates strong potentiation in combination with multiple antibiotics with efflux liabilities against wild-type and multidrug-resistant (MDR) P. aeruginosa.
- 7Nov, 2024
Efflux Pump Inhibitor (EPI) drug candidates appears in the August 13th special Antibiotic Alternatives issue of ACS Infectious Diseases. The paper titled “The CARB-X Portfolio of Nontraditional Antibacterial Products”
- 20Feb, 2025
On April 15, 2021, the World Health Organization (WHO) released their report titled “2020 Antibacterial Agents in Clinical and Preclinical Development” naming TAXIS Pharmaceuticals’ FtsZ inhibitor drug candidate TXA709 as one of only 2 (out of 26) antibacterials targeting WHO priority pathogens that meet all of the WHO innovation criteria (absence of known cross resistance, new class, new target; new mode of action).
Frank Carlo Pasqualone, MBA
Joe DePinto, MBA
Gregory G. Mario, MBA, President and CEO